Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality, age 65+ 79% Improvement Relative Risk Mortality, age 40-64 -32% Hospitalization, age 65+ 73% Hospitalization, age 40-64 26% c19early.org/pl Arbel et al. Paxlovid for COVID-19 EARLY TREATMENT Favors paxlovid Favors control
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Arbel et al., New England Journal of Medicine, doi:10.1056/NEJMoa2204919 (date from earlier preprint)
1 Jun 2022    Source   PDF   Share   Tweet
Retrospective 109,254 patients in Israel, 3,902 treated with nirmatrelvir, showing lower mortality and hospitalization with treatment for the subgroup of patients >65. Authors only provide subgroup results.
risk of death, 79.0% lower, HR 0.21, p = 0.03, treatment 2 of 2,484 (0.1%), control 158 of 40,337 (0.4%), NNT 321, adjusted per study, multivariable, Cox proportional hazards, age 65+.
risk of death, 32.0% higher, HR 1.32, p = 0.81, treatment 1 of 1,418 (0.1%), control 16 of 65,015 (0.0%), adjusted per study, multivariable, Cox proportional hazards, age 40-64.
risk of hospitalization, 73.0% lower, HR 0.27, p < 0.001, treatment 2 of 2,484 (0.1%), control 151 of 40,337 (0.4%), NNT 340, adjusted per study, multivariable, Cox proportional hazards, age 65+.
risk of hospitalization, 26.0% lower, HR 0.74, p = 0.44, treatment 1 of 1,418 (0.1%), control 13 of 65,015 (0.0%), adjusted per study, multivariable, Cox proportional hazards, age 40-64.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Arbel et al., 1 Jun 2022, retrospective, Israel, peer-reviewed, mean age 60.0, 12 authors.
Contact: ronen.arbel@gmail.com.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit